| Effect of holoBLG on Cat Allergic Patients (NCT05455749) | Allergy Therapeutics | 2021-10-04 |
| Andosan in Allergic and Asthma Patients (NCT05192720) | University Hospital, Akershus | 2021-08-31 |
| Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis (NCT04874714) | Inmunotek S.L. | 2021-04-30 |
| Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction (NCT04502966) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-11-05 |
| Adolescent Mite Allergy Safety Evaluation (NCT04541004) | ALK-Abelló A/S | 2020-09-23 |
| Demonstration of a Decongestant Effect of "Coldamaris Akut" Compared to Saline Nasal Spray. (NCT04532762) | Marinomed Biotech AG | 2020-08-04 |
| Demonstration of an Anti-allergic Effect in Subjects Treated With Callergin Nasal Spray in Comparison to Untreated Subjects and Subjects Treated With Vis Alpin® Alpensalz Nasal Spray, All Suffering From Grass Pollen Induced Rhinitis/Rhinoconjunctivitis (NCT04531358) | Marinomed Biotech AG | 2020-08-04 |
| A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber (NCT04176185) | ALK-Abelló A/S | 2019-11-04 |
| Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis (NCT03887026) | Emergo Therapeutics, Inc. | 2019-04-01 |
| Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study (NCT03682965) | Christopher Thompson, MD | 2018-09-28 |
| S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen (NCT04912076) | Odense University Hospital | 2018-09-17 |
| Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients (NCT03850626) | Leti Pharma GmbH | 2018-09-09 |
| Efficacy and Safety of Lertal® as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics (NCT03365648) | NTC srl | 2017-09-15 |
| Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Allergic Rhinoconjunctivitis Sensitized to House Dust Mites (NCT02881879) | Roxall Medicina España S.A | 2016-07-01 |
| Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy (NCT02556801) | HAL Allergy | 2015-09-01 |
| A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure Chamber (NCT02481856) | ALK-Abelló A/S | 2015-06-01 |
| Study for Evaluating Life Quality in Patients With Rhinoconjunctivitis (NCT02488447) | Roxall Medicina España S.A | 2015-05-01 |
| Nasal Mucus Proteome and Immunotherapy (NCT02159404) | Medical University of Graz | 2015-04-01 |
| An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy (NCT02069535) | ALK-Abelló A/S | 2014-04-01 |
| Evaluation of the Utility of an EEC for Assessing Efficacy of SIT in Pivotal Clinical Trials (NCT02297490) | Allergopharma GmbH & Co. KG | 2014-01-01 |
| MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009) (NCT01852825) | Merck Sharp & Dohme LLC | 2013-11-27 |
| A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects (NCT01966224) | Immunomic Therapeutics, Inc. | 2013-09-01 |
| Quality of Life in Allergic Rhinoconjunctivitis Patients Treated With Dialyzable Leukocyte Extracts (NCT02506998) | National Polytechnic Institute, Mexico | 2013-08-01 |
| A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid (NCT01707069) | Immunomic Therapeutics, Inc. | 2012-10-01 |
| SUBLIVAC FIX Phleum Pratense DT/DRF (NCT01682070) | HAL Allergy | 2012-09-01 |
| SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding (NCT01639768) | HAL Allergy | 2012-07-01 |
| Dose-response Study With Subcutaneous Immunotherapy of an Standardized Dermatophagoides Pteronyssinus (DPT) Extract (NCT01564017) | Roxall Medicina España S.A | 2012-05-01 |
| A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021) (NCT01535118) | ALK-Abelló A/S | 2012-01-01 |
| Vitamin D and Grass Pollen Specific Immunotherapy (NCT01466465) | Charite University, Berlin, Germany | 2011-10-01 |
| Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense (NCT01567306) | Roxall Medicina España S.A | 2011-10-01 |
| PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis (NCT01438463) | HAL Allergy | 2011-09-01 |
| Avanz Phleum Pratense Maintenance Dose (NCT01438827) | ALK-Abelló A/S | 2011-09-01 |
| An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy (NCT01454531) | ALK-Abelló A/S | 2011-06-01 |
| Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT) (NCT01489020) | Roxall Medicina España S.A | 2011-01-01 |
| Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis (NCT01490411) | Allergopharma GmbH & Co. KG | 2010-10-01 |
| Changes in Specific Immunoglobulin and Blood Basophil Activity During Subcutaneous Immunotherapy in Allergic Rhinitis (NCT01085526) | Aarhus University Hospital | 2010-02-01 |
| PURETHAL Grasses Rush Study (NCT01059266) | HAL Allergy | 2010-02-01 |
| Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense (NCT01489033) | Roxall Medicina España S.A | 2010-01-01 |
| Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU) (NCT01081574) | Faes Farma, S.A. | 2010-01-01 |
| Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX® (NCT02437786) | ALK-Abelló A/S | 2009-09-01 |
| Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC) (NCT00985296) | ORA, Inc. | 2009-09-01 |
| Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients (NCT00973453) | HAL Allergy | 2009-08-01 |
| A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis (NCT00812799) | Artu Biologicals | 2008-12-01 |
| A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinoconjunctivitis Following Exposure in the Allergen BioCube (NCT00985075) | ORA, Inc. | 2008-12-01 |
| Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration (NCT00777374) | University of Zurich | 2008-10-01 |
| A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine (NCT01740284) | ALK-Abelló A/S | 2008-09-01 |
| Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Parietaria Judaica (NCT00916760) | Laboratorios Leti, S.L. | 2008-02-01 |
| Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative (NCT00841516) | Allergopharma GmbH & Co. KG | 2007-12-01 |
| Tolerability of Grazax in Patients With Hayfever in Real Life Settings (NCT01433510) | ALK-Abelló A/S | 2007-11-01 |
| Long-term Efficacy and Safety Study With Oralgen Grass Pollen (NCT00824447) | Artu Biologicals | 2007-08-01 |
| Efficacy-safety Study of Sublingual Immunotherapy With Depigmented-polymerized Pollen Extracts to Treat Rhinoconjunctivitis (NCT00550875) | Laboratorios Leti, S.L. | 2007-06-01 |
| Normal Values of Facial Thermography (NCT00411606) | West Penn Allegheny Health System | 2006-12-01 |
| Efficacy and Safety of Grass Pollen Sublingual Immunotherapy (NCT00567346) | Artu Biologicals | 2006-12-01 |